FDA Halts Regenxbio Gene Therapy Trial Again Amid Safety Issues
By Editor • August 24, 2026 • 1 min read
The FDA has once more suspended trials for Regenxbio's gene therapy targeting Hunter syndrome due to safety concerns.
Five patients were found to have small masses on their spines, though they reported no related symptoms. This pause follows a previous incident where a boy developed a brain tumor linked to a similar therapy.
Source: www.statnews.com
#FDA #gene therapy #Hunter syndrome #Regenxbio #safety concerns
